drugset / Trial / NCT01860625

A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects

NCT01860625

Phase 1 Completed 36 enrolled Icure Pharmaceutical Inc.
RandomizedSingle-groupSingle-blindTreatment

Summary

Study of the Safety, tolerability and pharmacokinetics with single dose of donepezil patch in healthy male subjects.

Timeline

Start
2013-04
Primary completion
2013-12
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 43.75 mg Other
Subject Donepezil Small molecule 87.5 mg Other
Subject Donepezil Small molecule 175 mg Other

Indications